Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 17, 2025

Forget AT&T, Buy These 3 Promising Telecom Stocks Instead for 2026

View original at finance.yahoo.com
Forget AT&T, Buy These 3 Promising Telecom Stocks Instead for 2026 The telecom sector witnessed healthy demand trends in 2025 with an accelerated pace of 5G deployment and increased fiber densification, driven by a rising user propensity to stay abreast of the latest digital innovations…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AT&T's wireline division is struggling with persistent losses in access lines due to competitive pressure from VoIP providers and cable companies

    80% confidence

  • Top 50% of Zacks-ranked industries outperform bottom 50% by a factor of more than two to one

    80% confidence

  • The telecom sector witnessed healthy demand trends in 2025 with accelerated 5G deployment and increased fiber densification

    80% confidence

  • 5G transition is expected to be disruptive, creating new growth avenues for industries across the board

    80% confidence

  • 5G is touted as the primary catalyst for Generative AI and next-generation IoT services

    80% confidence

  • Growth to be driven by secular demand for 5G wireless, fiber and 3D sensing

    80% confidence

  • Standardization of 5G is the cornerstone for digitizing industries and broadband

    80% confidence

  • AT&T may face challenges in meeting short-term debt obligations with current ratio of 1.01 and cash ratio of 0.38

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com